Evaluation of HIV-Negative Patients With Low CD4+ T Lymphocyte Counts
NCT00001319 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2008-03-04
Summary
This study will evaluate HIV-negative patients with unusually low levels of CD4+ T lymphocytes (a type of white blood cell) to learn more about the clinical symptoms, cause, immunology, and biology of this problem. CD4+ T lymphocytes play an important role in immune function, and low counts may leave people susceptible to unusual infections. CD4+ T cell deficiencies are most often associated with HIV infection.
Patients 8 years of age and older with CD4+ T cell counts below 300 cells/mm3 who test negative for HIV infection by standard blood tests may be eligible for this study. Patients' family members and partners may also be enrolled to investigate the possible role of a genetic factor or exposure to some agent in this problem.
Patients will be evaluated at the NIH Clinical Center at least once, and generally two or more times. The evaluations, which may be done on an inpatient or outpatient basis, will include some or all of the following tests and procedures:
* Complete physical examination.
* Medical history, including questions about sexual contacts, intravenous drug use, travel, blood transfusions, previous illnesses, including sexually transmitted diseases, and health of family members.
* Urine test.
* Blood tests for routine and research purposes, including tests for HIV, hepatitis, syphilis and other infections, evaluation of immune function, and culture for viruses in the HIV family. No more than 1 pint of blood will be drawn every 6 weeks.
* Pregnancy test for women of childbearing potential.
* Skin tests for tuberculosis and immune function. These tests involve injecting a small amount of the substance to be tested just under the skin and looking for a raised area 1 to 2 days later.
* Apheresis. Whole blood is collected through an arm vein (similar to donating blood), and circulated through a cell separator machine, where it is spun to separate the components. The red cells are then returned to the patient either through the same needle or through a needle in the other arm, and the plasma and white cells are extracted for study. The procedure, which takes 1 to 2 hours, may be repeated up to 3 times.
Family members will have 60 cc (4 tablespoons) of blood drawn to determine CD4+ T cell counts.
Conditions
- CD4 Lymphocytopenia
- Idiopathic CD4 Positive T Lymphocytopenia
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
lead NIH
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1992-09-30
- Completion
- 2003-07-31
Countries
- United States
Study Locations
More Related Trials
-
Immune Responses to HIV in Blood Cells in HIV-Infected and HIV-Uninfected Volunteers
NCT00027482 ·Status: COMPLETED
-
A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection
NCT05582694 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Multicenter, Double-Blind, Phase III, Adjuvant-Controlled Study of the Effect of 10 Units of HIV-1 Immunogen (Remune) Compared to Incomplete Freund's Adjuvant (IFA) Alone Every 12 Weeks on AIDS-Free Survival in Subjects With HIV Infection and CD4 T-Lymphocytes Between 300 and 549 Cells/microL Rega
NCT00002359 ·Status: COMPLETED ·Phase: PHASE3
-
Human Immune Responses Toward HIV-1 Envelope Antigens
NCT01344941 ·Status: COMPLETED
-
A Study to Evaluate the Effect of Cimetidine on CD4 Lymphocyte Counts in HIV Infection
NCT00002092 ·Status: COMPLETED ·Phase: NA
-
A Pilot Study of Allogeneic Lymphocyte Transfer in HIV Infection
NCT00000852 ·Status: COMPLETED ·Phase: NA
-
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
NCT01777997 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Effectiveness of Immunotherapy With Autologous HIV-Specific CD8 Cells in HIV Infected Adults
NCT00110578 ·Status: COMPLETED ·Phase: PHASE1
-
Redirected MazF-CD4 Autologous T Cells for HIV Gene Therapy
NCT01787994 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase I Study of Recombinant CD4(rCD4) in Patients With AIDS and AIDS-Related Complex
NCT00002005 ·Status: COMPLETED ·Phase: NA
-
The Role of Naive T-Cells in HIV Pathogenesis
NCT00206531 ·Status: UNKNOWN
-
A Pilot Study of Immunization With HIV-1 Antigen Pulsed Allogenic Dendritic Cells in HIV-Infected Asymptomatic Patients With CD4+ T Cells > 350 Cells/mm3
NCT00001064 ·Status: TERMINATED ·Phase: NA
-
Leukapheresis to Obtain Plasma or Lymphocytes for Studies of HIV-infected Patients, Including Long-term Non-progressors
NCT00029445 ·Status: RECRUITING
-
CD4-ZETA Gene Modified T Cells With and Without Exogenous Interleukin-2 (IL-2) In HIV Patients
NCT01013415 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4 Immunoglobulin (rCd4-IgG) Administered by Intravenous Bolus in Patients With AIDS and AIDS Related Complex
NCT00000675 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Effects of Interleukin-12 (rhIL-12) in HIV-Positive Patients With CD4 Cell Counts Less Than 50 Cells/mm3 or 300-500 Cells/mm3
NCT00000857 ·Status: COMPLETED ·Phase: PHASE1
-
Use of Labeled Glucose to Study Lymphocyte Replication and Survival in HIV-Infected Patients
NCT00001651 ·Status: TERMINATED ·Phase: NA
-
Using the Drug Thalidomide to Stimulate T Cells in HIV-Infected People
NCT00053430 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 (rCD4) in Patients With AIDS and AIDS-Related Complex
NCT00002004 ·Status: COMPLETED ·Phase: PHASE1
-
Redirected High Affinity Gag-Specific Autologous T Cells for HIV Gene Therapy
NCT00991224 ·Status: COMPLETED ·Phase: PHASE1
-
Safety of the Candidate Vaccine C4-V3 Alone or With Interleukin-12 (IL-12) in HIV-Infected Patients Receiving Effective Anti-HIV Drug Therapy
NCT00005779 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluate the Safety, Immunologic, and Virologic Responses of Donor Derived (DD) HIV-Specific T-cells (HST) in HIV-infected Individuals Following Allogeneic Bone Marrow Transplantation (alloRESIST)
NCT04248192 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases
NCT04640142 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
CD4 CAR+ ZFN-modified T Cells in HIV Therapy
NCT03617198 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Phase I Study to Evaluate the Safety and Immunogenicity of HIV-1 Immunogen in Children With HIV-1 Infection
NCT00001445 ·Status: COMPLETED ·Phase: PHASE1